Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01714739
Title A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

Advanced Solid Tumor

Therapies

Lirilumab + Nivolumab

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | CAN


No variant requirements are available.